DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Humalog Mix50 / 50 (Insulin Lispro Subcutaneous) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Humalog Mix50/50, a mixture of 50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin), is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia. Based on cross–study comparisons of the pharmacodynamics of Humalog Mix50/50 and Humulin 50/50, it is likely that Humalog Mix50/50 has a more rapid onset of glucose–lowering activity compared with Humulin 50/50 while having a similar duration of action. This profile is achieved by combining the rapid onset of Humalog with the intermediate action of insulin lispro protamine suspension.

DOSAGE AND ADMINISTRATION

Table 1The information supplied in Table 1 indicates when peak insulin activity can be expected and the percent of the total insulin activity occurring during the first 4 hours. The information was derived from 3 separate glucose clamp studies in nondiabetic subjects. Values represent means, with ranges provided in parentheses.: Summary of Pharmacodynamic Properties of Insulin Products (Pooled Cross–Study Comparison)

Insulin Products

Dose, U/kg

Time of Peak Activity, Hours After Dosing

Percent of Total Activity Occurring in the First 4 Hours

Humalog

0.3

2.4
(0.8 – 4.3)

70%
(49 – 89%)

Humulin R

0.32
(0.26 – 0.37)

4.4
(4.0 – 5.5)

54%
(38 – 65%)

Humalog Mix75/25

0.3

2.6
(1.0 – 6.5)

35%
(21 – 56%)

Humulin 70/30

0.3

4.4
(1.5 – 16)

32%
(14 – 60%)

Humalog Mix50/50

0.3

2.3
(0.8 – 4.8)

45%
(27 – 69%)

Humulin 50/50

0.3

3.3
(2.0 – 5.5)

44%
(21 – 60%)

NPH

0.32
(0.27 – 0.40)

5.5
(3.5 – 9.5)

14%
(3.0 – 48%)

NPL component

0.3

5.8
(1.3 – 18.3)

22%
(6.3 – 40%)

Humalog Mix50/50 is intended only for subcutaneous administration. Humalog Mix50/50 should not be administered intravenously. Dosage regimens of Humalog Mix50/50 will vary among patients and should be determined by the healthcare provider familiar with the patient’s metabolic needs, eating habits, and other lifestyle variables. Humalog has been shown to be equipotent to Regular human insulin on a molar basis. One unit of Humalog has the same glucose–lowering effect as one unit of Regular human insulin, but its effect is more rapid and of shorter duration. The quicker glucose–lowering effect of Humalog is related to the more rapid absorption rate of insulin lispro from subcutaneous tissue.

Direct comparison between Humalog Mix50/50 and Humulin 50/50 was not performed. However, a cross–study comparison shown in Figure 3 suggests that Humalog Mix50/50 has a duration of activity that is similar to Humulin 50/50.

The rate of insulin absorption and consequently the onset of activity are known to be affected by the site of injection, exercise, and other variables. As with all insulin preparations, the time course of action of Humalog Mix50/50 may vary considerably in different individuals or within the same individual. Patients must be educated to use proper injection techniques.

Humalog Mix50/50 should be inspected visually before use. Humalog Mix50/50 should be used only if it appears uniformly cloudy after mixing. Humalog Mix50/50 should not be used after its expiration date.

HOW SUPPLIED

Humalog Mix50/50 [50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)] is available in the following package sizes: each presentation containing 100 units insulin lispro per mL (U-100).

 10 mL vials

NDC 0002–7512–01 (VL-7512)

 5 x 3 mL disposable insulin delivery devices (Pen)

NDC 0002–8793–59 (HP-8793)

 5 x 3 mL disposable insulin delivery devices (KwikPen™)

NDC 0002–8798–59 (HP-8798)

Storage — Humalog Mix50/50 should be stored in a refrigerator [2° to 8°C (36° to 46°F)], but not in the freezer. Do not use Humalog Mix50/50 if it has been frozen. Unrefrigerated [below 30°C (86°F)] vials must be used within 28 days or be discarded, even if they still contain Humalog Mix50/50. Unrefrigerated [below 30°C (86°F)] Pens, and KwikPens must be used within 10 days or be discarded, even if they still contain Humalog Mix50/50. Protect from direct heat and light. See table below:

Not In-Use (Unopened) Room Temperature [Below 30°C (86°F)]

Not In-Use (Unopened) Refrigerated

In-Use (Opened) Room Temperature [Below 30°C (86°F)]

 10 mL Vial

28 days

Until expiration date

28 days, refrigerated/room temperature.

 3 mL Pen and KwikPen (disposable)

10 days

Until expiration date

10 days. Do not refrigerate.

Literature issued September 6, 2007

KwikPens manufactured by
Eli Lilly and Company, Indianapolis, IN 46285, USA
Pens manufactured by
Eli Lilly and Company, Indianapolis, IN 46285, USA
Vials manufactured by
Eli Lilly and Company, Indianapolis, IN 46285, USA or
Lilly France, F-67640 Fegersheim, France

for Eli Lilly and Company, Indianapolis, IN 46285, USA

www.humalog.com

Copyright © 2007, Eli Lilly and Company. All rights reserved.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017